A Next-generation targeted immuno-oncology therapy

ended

In spite of enormous medical progress, aggressive forms of cancer remain one of the leading causes of death across the globe. Metastasized prostate, lung, breast and colon cancer account for a combined mortality of approximately 0,8 M lives in Europe per year. Immunotherapies, activating patient’s own immune system to target and destroy tumor cells, have shown enormous promise in the treatment of metastatic forms of cancer, creating a huge market with a €100B potential in 2022. However, these drugs are only effective in 15-25% of patients, and their use is associated with severe side effects. Therefore, there is an unmet medical need for next-generation of cancer immunotherapies with improved safety and consistent efficacy in a broader patient population. TargImmune, is a Switzerland based company with a mission to develop novel targeted immuno-oncology drugs that will improve the treatment of patients with aggressive tumors. Using our proprietary treatment technology based on the targeted intracellular delivery of an RNA-analogue inside the tumor, we will provide novel systemic immune therapy for metastasized cancer with less side effects and improved effectiveness across all patient populations. Currently we have 3 drugs in development for prostate, breast cancer and solid tumors. All potential pipeline candidates address a highly attractive immune-oncology market, with the total addressable market for our first asset of €1.7B. The product is predicted to generate €466M of cumulative annual revenues through 10 % royalties over sales in the first 5 years, as a part of licensing deal with a large pharmaceutical company. After initial investment round, we currently seek for additional funding to further develop our pipeline candidates. In the NEXIM project, we will finalize an investor-ready business plan, required to ensure additional investments. The project will also include an analysis of the competitor and investor landscape and market positioning.